Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Gcbr, you are right and we will do our best to keep confusion down on the board. We cannot jump to conclusions, but when a poster lends enough posts to gives us ammo; well, we email them to Matt and he takes care of business.
IVRT
DNAP trading is brisk this morning, any news?
Marcos,nice board you have here! I think once the costly gold stocks get too high for most investors, the otc bb pinks and penny golds will start to fly, imho, then this board will start jumping with posters!
Happy trading to you
IVRT
American Bonanza (ABZGF:bb pink) Here is an article about a little known gold stock play: http://www.clivemaund.com/article.php?art_id=63
Please do not bring another board's issues to this board! Personal attacks, of other board members do not belong on this board! This type of posting is wasteful and does not bring any good to the board members as a whole. Your posts will be deleted! If you continue, your posts will be forwarded to Ihub. I do not have a problem with the posters on this board, but when ya gotta post personal attacks about people, well that is wrong and I have a problem with that!
Happy trading too!!!
IVRT
Long_haul007, I think that is the idea! This where you belong, until you realize this is Matt's Ihub and you gotta follow the rules!
Happy trading too!
IVRT
ot: Manti, with regards to who posts on Ihub boards is Ihub business. I think you should email Ihub for assistance related to your question!
IVRT
mingwan0, what is the second phase in this pr?. The project was divided into two phases and the first has been approved. Did I miss something here? TIA
IVRT
mjam, I agree this is really monumental news! Dnap has landed a subcontracting job that may very well lead to some interesting deals and partnerships! Time will tell!
IVRT
What's up with sudden vol increase?
blue, according to your post 3839, you know why!
IVRT
tomtrc, if you want to post to the board, then go for it! Just do not expect personal attacks to remain on the board! They will be deleted! As for a pink sheets, Ihub and DNAP, readers here can make up their owns minds about DNAP, whether it is pro or con! IF your looking to create a RB environment of personal attacks, you are out of luck!
Happy trading to you!
IVRT
radean2000, I have read hwan's posts and I suspect that Hwan has a good command of the English language! If you read Hwan's posts, you may come to the same conclusion. It just appears that the later posts seem to digress more than the earlier posts!
IVRT
hwan this board is not for disruptive idle chatter! Please correct your human mistakes before you post! Thanks for your attention to this matter!
IVRT
Long_haul007, you are beginning to irritate the board! If you cannot post meaning dialog, it would be better that you post nothing at all. I believe that you are trying to disrupt this board. If that be the case, we have collected all of your posts and are waiting for the balance to tip against you. You can be banned from the board for disruption and I believe that is what you want! If you cannot play by the rules, the rules will ultimately play you!
IVRT
What does CMIH have to do with DNAP? This clutters up the board! Please use the private message function for this purpose!
PLEASE!
IVRT
Spam - a message that is being posted promoting other sites, stock-related or not, that has no use in the discussion (for example, if your board is about Ford Motors, a link promoting amazing returns running a home-based business is worthless to the discussion).
spook, I do not disagree with the loss, but we are all aware as you for sometime, that DNAP is a Speculative venture in the development phase. Consequently, DNAP does not have a cash flow positive environment at this point in time. What pray tell are you trying to get at? Research and development costs cash, and the last time I looked people did not work for free in corporate America. Executives today corner some hefty salaries, good or bad, why should DNAP be any different? It is quite possible that the 7 players at DNAP are making below industry averages. Certainly, some are not going to cash in their stock options and awards tomorrow due to restrictions.
Debt goes hand in hand with R & D.
IVRT
'spook' you have raised some good concerns! I think your questions should be directed at dnap as well. I am interested in any responses you may get from DNAP, if you email them, concerning these questions.
IVRT
OT, Arch, I am looking forward to your pics! I have seen some of your pics at your photo album site. Is the Victorian home (winter setting, I believe) your house?
IVRT
Long_haul007 it would be wise of you to email IHUB support, for help on this subject!
IVRT
Please do not bring your petty differences that you have with posters, from other stock board to this board. This is considered disruption! You have a private message function for that purpose, and by all means use it til you turn blue! Please do not assume that, just because a poster's name on this board is the same as one on RB for example, that they are one in the same. Please respect the posters on this board; I do not think they want to waste their time reading this type of posting.
Thanks!
IVRT
Here's a link to an old PR from Waggoner. It would be interesting to know what DNAP had to say with regard to the following: ...technologies underlying predictive pharmacogenomics will yield drugs that are more compatible with an individual patient’s ability to metabolize medicine and less likely to produce adverse side effects...
Looks like Tony learned something from this discussion, about drugs and his company. Is DNAP merging or partnering in the near future? It takes a lot of $$$$$$$$$ for NDA and trials from phase I thru after market testing. I am very interested in this new direction DNAP is embarking on!
http://www.chireports.com/content/reports/predictive_medicine.asp
Please respect the board and not use cap locks to post entire messages! There is no need to be flamboyant.
hwan, give them a call, it is your idea and you should run with it. Let us know what you find!
IVRT
Please use the private message function available to you for personal issues you have with other posters.
Please respect other board members in this regard!
Thanks!!!!!
IVRT
Everyone please read this post: What Messages can be Deleted on this board?
I have supplied a link too!
http://www.investorshub.com/boards/complex_terms.asp
...Moderators of stock-specific boards are allowed to immediately remove any post for Admin review that falls into the following categories: Duplicate, Personal Attack, Spam. Each hidden/removed post is reviewed by Admin and either left removed or restored...
This is general information and I would like to let everyone know that the DNAP board does not allow for disruptive posters. It is not our intent to delete posts on the board as long as they follow Ihub's tos for stock boards. If a poster continues to disrupt the board, their posts will be forwarded to Ihub for review! None of us wants another RB chaotic board!!!!
IVRT
Gandolf3, you asked a great question! Why don't you email DNAP and ask them for an answer? I am sure they could give a reply a lot better than us! Then you could post their answer here and we can all read it! Here is their email contact address:
admin@dnaprint.com
IVRT
Here's an article on ACE and ARB!
There are angiotensin converting enzyme (ACE) inhibitors drugs and angiotensin receptor blockers (ARB).
Cardiovascular Disorders Ask The Expert
Rationale for Combining ACE Inhibitors and Angiotensin Receptor Blockers
Posted 10/23/2002
from Medscape Primary Care
Question
What is the rationale behind combining angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs)?
Stephen George, MD
Response
from Ken Grauer, MD, 10/23/2002
At first glance, one might question the concept of using the combination of an ACE inhibitor and an ARB in the same patient. Both classes of drugs work to inhibit the renin-angiotensin-aldosterone (RAA) system. Combined use would therefore seem redundant.
In actuality, the mechanism of action of ACE inhibitors and ARBs is not exactly the same. Although it is true that the end result of each agent is angiotensin-II inhibition, the site of action of ARBs is more distal than that of ACE inhibitors. ACE inhibitors block the action of the ACE. As a result, angiotensin-I is no longer converted to angiotensin-II. ACE is also responsible for breakdown of bradykinin, which is an inflammatory mediator and vasodilator. ACE inhibition therefore leads to accumulation of bradykinin, which serves to augment the amount of vasodilatation produced by ACE-inhibitor drugs. Just how potent the vasodilatory effect produced by bradykinin will be in any given patient is uncertain. Bradykinin is also important because it may be responsible for the adverse effects of cough and angioedema that occur with ACE inhibitors, but which are rare with ARBs.
In contrast to ACE inhibitors, ARBs do not affect ACE, and therefore do not result in bradykinin accumulation. Instead, ARB drugs produce a more distal (end-receptor blockade) effect that inhibits angiotensin-II. Because enzyme systems other than ACE are involved in angiotensin production, this more distal effect of ARB drugs may actually produce a greater overall angiotensin-II inhibitory effect than ACE inhibitors. However the effect of bradykinin on various vascular beds may counteract the somewhat lesser overall inhibition of angiotensin-II, so that the clinical potency of ACE inhibitors and ARBs for blood pressure reduction is comparable in most studies.
Use of ACE inhibitors is usually preferred initially for treatment of heart failure if there are no contraindications, because of the much greater body of supportive literature on the use of this class of drugs compared with the ARBs. However, when bothersome cough or other idiosyncratic reaction prevents use of ACE inhibitors, substitution of an ARB is usually recommended.
With this background, I offer the following rationale for considering use of both an ACE inhibitor and ARB in the same patient: an augmented clinical effect might be seen in selected patients because the mechanism of action of these 2 classes of drugs, while similar, is not identical. Clinically, combined use is most often contemplated in the treatment of heart failure. Support for this concept was seen in the Val-HeFT Trial, in which the addition of an ARB to either an ACE inhibitor or a beta-blocker had a beneficial effect on morbidity and mortality.[1,2] However, post-hoc analysis of this trial failed to show additional benefit from use of an ARB if both an ACE inhibitor and a beta-blocker were already being used. That stated, it should be remembered that results from evidence-based trials represent statistical likelihood of benefit of a drug (ie, "average effect") in a large population, but does not rule out potential for benefit in an individual patient. In view of Val-HeFT results, however, it is likely that if a patient with chronic heart failure is already on full doses of an ACE inhibitor and a beta-blocker, addition of an ARB will probably not exert a large beneficial effect. However, given our direction as clinicians to individualize patient care in the practice of the "art" of medicine, it is clearly reasonable to consider adding an ARB to the regimen of an individual with heart failure who is already taking an ACE inhibitor and beta-blocker (as well as an optimal diuretic dose and other standard therapy) if he has not optimally responded to previous treatment. This is especially relevant if persistent hypertension remains problematic.
--------------------------------------------------------------------------------
References
Cohn JN. Cardiology. Improving outcomes in congestive heart failure: Val-HeFT. Valsartan in Heart Failure Trial. 1999;91(suppl 1):19-22.
Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675.
About the Panel Members
Ken Grauer, MD, Professor of Community Health and Family Medicine and Assistant Director, Family Practice Residency Program, College of Medicine, University of Florida, Gainesville.
Medscape Primary Care 4(2), 2002. © 2002 Medscape
Theo, DougS and I are the moderators for this board! John has stepped down to concentrate on the other boards that he moderates for here at Ihub. If you have any concerns about posts on "THIS BOARD," please private message one of us! Have a good day and happy trading to you!
IVRT
I am finally glad to see you folks posting here. It has been lonely over here, but the lack of BS from RB has made the months refreshing here. I want to welcome you to the DNAP board. We can delete many messages such as spam and abusive language and etc.
If you have issues with fellow posters here, please use the private reply button amongst yourselves or email sysop for help. Over the last year or two we have had minimal problems with spam and wholesale idiotic posters.
Glad to see some of the old DNAP posters here as well as new ones too!
IVRT
Looks great John :)! eom
Jmhollen is the new DNAP board assistant! Not a big thing, but I wanted to let everyone know. I have not heard from cerealman in along time, and removed him accordingly!
Have a good day all!
IVRT
The Revolution in Forensic Genomic Starts Now
DETERMINE RACE PROPORTIONS FROM CRIME SCENE DNA
- The Revolution in Forensic Genomic Starts Now -
DNAPrint genomics, Inc. has applied the most recent advancements in human genomic technology for the deciphering of an individual's race. We are proud to introduce to the forensic community DNA WITNESS 2.0, a genetic test for the deduction of the heritable component of race, called Biogeographical Ancestry (BGA). This test is the first of its kind, resulting from three (3) years of genomic research, and is the beginning of a revolution in criminal investigations. This test provides not only the majority population affiliation (i.e. Indo European, Sub-Saharan African, East Asian or Native American), but the admixture, as well (i.e. 82% East Asian and 18% Indo-European mix).
This new test provides important Forensic Anthropological information relevant for a wide variety of investigative situations. When biological evidence is gathered, an investigative team can use DNA WITNESS 2.0 to construct a partial physical profile from the DNA and in many cases learn details about the donor's appearance, essentially permitting a partial reconstruction of their driver's license photo. How many times have you wished an unknown suspect left his driver's license at the scene - even if the unique identifiers were smudged?
Recognizing the need for genomics-based physical profiling tools, DNAPrint genomics is the first company to apply human genome power for the precise estimation of Biogeographical percentages from DNA.
Because physical profiling from DNA will effectively offer an objective "eyewitness" for each crime, where biological evidence has been left, the implications for saving investigative dollars and maximizing the efficiency of our criminal justice system are profound. STR identity tests form the cornerstone of forensic DNA analysis, but they are not useful for the assumption of race or any other physical traits, because the STR markers were not selected for the ability to do so. Other non-DNA based investigative work tends to rely on less scientifically robust methodology. For example, "eyewitnesses":
" Are not always reliable, are subjective and sometimes misleading. Most of the felons released from death row, based on DNA testing, were convicted based on faulty eyewitness testimony.
" Are not available for each crime.
Until now, no scientific method has been available to help investigators learn what a DNA donor looks like. DNAPrint's DNA WITNESS 2.0 product represents the first wave of a genomics revolution that is afoot in forensics science. We are applying the test to actual casework and we've performed testing for a number of high profile murder/rape cases, where DNA was left at the crime scene.
DNA WITNESS 2.0 could provide additional detail to current cases or cold cases could be re-visited. The results indicating to detectives what population groups to include or exclude in their investigation. The goal of the product is simple, help you focus your investigation and identify from whom a forensic sample was derived. Effectively, what we have done is harness our increasing knowledge of human genomics to help you get the job done. Wouldn't you like to have a DNA eyewitness for your most important cases?
We would be pleased to provide you a CD-ROM of the validation experiments, which was performed for this test on over 2,000 DNA samples.
Please contact us to discuss the possibility of using DNA WITNESS 2.0 on your cold, current, or next case.
Zach Gaskin
Technical Director, Forensic Genomics
941-366-3400
zgaskin@dnaprint.com
Copyright DNAPrint genomics © 2000
900 Cocoanut Ave.
Sarasota, FL 34236
(941) 366-3400
Fax # (941) 952-9770
GPXME moving, up 0.08 on news! http://finance.lycos.com/home/news/story.asp?story=34280683
DNAPrint Launches Ancestry 2.0 Forensic Profiling Service and Immediately Impacts Several Criminal Investigations
http://www.pinksheets.com/quote/news.jsp?url=fis_story.asp%3Ftextpath%3DCOMTEX%5Cpr%5C2003%5C05%5C02...
DNAPrint genomics Appoints Richard Gabriel as President and CEO
http://finance.lycos.com/home/news/story.asp?story=33782252
Happy New Year 2003!!!!!!!!!!
DNAPRINT GENOMICS INC 0001127354 10QSB
http://www.pinksheets.com/quote/print_filings.jsp?url=%2Fredirect.asp%3Ffilename%3D0001070876%252D02...